Evidence map›Paper›PMID 40266141›Full record

ArticleVaccines2025

Foot-and-Mouth Disease Vaccines by Design; Production of Capsid-Modified Foot-and-Mouth Disease Viruses with Improved Cell Culture Growth.

Stephen Berryman, Femke Feenstra, Amin Asfor, Jose Coco-Martin, Terry Jackson, Tobias J Tuthill

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Opposing fates: a bipolar cellular model for FMDV replication shaped byFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen BerrymanPirbright Institute, Ash Road, Woking GU24 0NF, UK.
Femke FeenstraBoehringer Ingelheim Animal Health Netherlands BV, P.O. Box 65, 8200 AB Lelystad, The Netherlands.
Amin AsforPirbright Institute, Ash Road, Woking GU24 0NF, UK.
Jose Coco-MartinBoehringer Ingelheim Animal Health Netherlands BV, P.O. Box 65, 8200 AB Lelystad, The Netherlands.
Terry JacksonPirbright Institute, Ash Road, Woking GU24 0NF, UK.
Tobias J TuthillPirbright Institute, Ash Road, Woking GU24 0NF, UK.ORCID 0000-0002-6582-388X

Funding

Biotechnology and Biological Sciences Research Council BB/N007298/1
6 · The paper itself

Abstract

BACKGROUND/

objectivesVaccination is important for controlling foot-and-mouth disease (FMD) in endemic regions and to lessen the effects of outbreaks in FMD-free countries. The adaptation of FMD virus to BHK cells is a necessary but time-consuming and costly step in vaccine production and can prove problematic for some isolates. Adaptation is, in part, driven by receptor availability and selects variants with altered receptor specificity that result from amino acid substitutions in the capsid proteins.

methodsTo bypass the need for cell culture adaptation, we generated chimeric viruses with field-strain capsids and introduced amino acid substitutions associated with cell culture adaptation. We targeted two sites on the capsid: the canonical heparan sulphate binding site and the icosahedral 5-fold symmetry axes.

resultsOur results show that some viruses with unmodified wild-type (wt) capsids grew well in BHK cells (suspension and adherent), whereas others showed poor growth. For viruses that showed good growth, the introduction of amino acid changes associated with cell culture adaptation improved the rate of growth but not virus titres or yields of 146S particles, whereas growth and 146S yields for viruses that grew poorly in BHK cells were greatly enhanced by some of the amino acid changes. For the latter viruses, the introduced changes did not appear to adversely affect virion stability or antigenicity.

conclusionsFor FMD viruses that grow poorly in BHK cells, this approach could be a viable alternative to protracted adaptation by serial passage and could expedite the production of a new vaccine strain from a field virus.

Indexed as

FMDVheparan sulfatereverse geneticstissue culture adaptationvaccine

Identifiers

PMID40266141
PMCPMC11945908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.